TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03715764

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy assessment
Description: Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.

Intervention type: OTHER
Group type: OTHER
Intervention: Physician assessment
Description: Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
Study: NCT03010163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Fair
Description: Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Fair
Description: Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
Study: NCT01572337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Study: NCT03010163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Fair
Description: Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Fair
Description: Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
Study: NCT03598244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT03010163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
Study: NCT03598244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray imaging
Study: NCT04602611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncology Nurse Navigation
Description: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Study: NCT04464707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Dose A or Dose B subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04369911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
Study: NCT04323553

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulsed-field gel electrophoresis and whole genome sequencing
Description: Comparison of the two different techniques

Intervention type: OTHER
Intervention: Data collection
Description: Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
Study: NCT03853434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: Angiographic embolization
Study: NCT04490109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B244
Description: B244 suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B244
Description: B244 suspension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle suspension
Study: NCT02582073

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (0.5ml)
Study: NCT01751737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Imaging
Description: After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
Study: NCT04312399

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid
Study: NCT02582073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.5ml)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.5ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (1.0ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (1.0ml)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (1.0ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL (0.5ml) 5100SU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL (1.0ml) 10200SU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL (1.0ml) 18200SU

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grass MATA (0.5ml) 5100SU
Study: NCT01746121

Intervention type: GENETIC
Intervention: Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.

Intervention type: GENETIC
Intervention: Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.
Study: NCT03018418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
Study: NCT03994250

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinematic Alignment for total knee replacement surgery
Description: Using Kinematic Alignment for total knee replacement surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical Alignment for total knee replacement surgery
Description: Using mechanical alignment for total knee replacement surgery
Study: NCT04166409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03010163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Daily healthy living advice and encouraging messages about walking through text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Daily healthy living advice and encouraging messages about walking through text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Network Support
Description: Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Network Support
Description: Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
Study: NCT01852578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
Study: NCT00162201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.
Study: NCT02412423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-transplantation cyclophosphamide
Study: NCT02733068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Description: 0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HPV-16/18 placebo
Description: 0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
Study: NCT01961388

Intervention type: DRUG
Intervention: Bay G5421 Glucobay
Description: Oral, dosage of Acarbose as per the directions of treating physician

Intervention type: DRUG
Intervention: Metformin
Description: Oral, dosage of Metformin as per the directions of treating physician
Study: NCT04267796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Complete aerobic training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Complete aerobic training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive diet recommendations from health coach or registered dietitian

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Receive diet recommendations from health coach or registered dietitian

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00642941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Study: NCT04267796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Complete high-resistance circuit training sessions
Study: NCT04267796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Complete high-resistance circuit training sessions
Study: NCT03104517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMDC-USR (iltamiocel)
Description: Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
Study: NCT01999361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: treatment with myfortic
Study: NCT04262830

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging (MRI)
Description: Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics

Intervention type: OTHER
Intervention: Accelerometer physical activity monitoring
Description: Measurement of physical activity using hip-worn accelerometer.
Study: NCT00642941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Study: NCT02693535

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab and Pertuzumab
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Vemurafenib and Cobimetinib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Regorafenib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab and Ipilimumab
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Abemaciclib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Talazoparib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab and PHESGO
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab and Talazoparib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Entrectinib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Larotrectinib
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Tucatinib plus Trastuzumab Subcutaneous (SC)
Description: drug

Intervention type: DRUG
Group type: OTHER
Intervention: Futibatinib
Description: drug
Study: NCT04178915

Intervention type: DIAGNOSTIC_TEST
Intervention: Bood leukocyte subsets
Description: Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)

Intervention type: DIAGNOSTIC_TEST
Intervention: The cholesterol content of the cell membrane of T-cells and monocytes
Description: The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
Study: NCT00024622

Intervention type: DRUG
Intervention: 18F-Fluoro-L-dopa

Intervention type: DRUG
Intervention: 18F-Fluoro-L-dopa

Intervention type: DRUG
Intervention: O-15 Water

Intervention type: DRUG
Intervention: O-15 Water

Intervention type: DRUG
Intervention: O-15 Water
Study: NCT00640380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve stimulation
Description: CPVB with NS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loss of resistance to air
Description: CPVB with LOR
Study: NCT02816021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 300 mg by mouth daily for 15 days (Days 1-15) of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 300 mg by mouth daily for 15 days (Days 1-15) of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
Study: NCT02412891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroShield device
Description: The UroShield device is Consists of two units:Actuator and Driver.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham UroShield device
Study: NCT00962741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
Study: NCT04225676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight.
Study: NCT00951236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: One cortisone injection
Description: Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two cortisone Injections
Description: Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
Study: NCT00760942

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac special care 30
Description: Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac human milk fortifier
Description: Powdered human milk fortifier.